RxDoctor Payments DataLook up a doctor →

Cristina Arriens, MD

Rheumatology · Oklahoma City, OKNPI 1861618183

Payments from drug & device makers

$1,830,063in general payments, 2019–2025

Across 491 payments — averaging $3727.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$674K
  • Eli Lilly$325K
  • GSK$205K
  • Astrazeneca UK Limited$188K
  • Takeda Pharmaceuticals U.S.A., Inc.$92K
  • Genentech, Inc.$83K
  • plus $262K from 11 others
$18,259in research payments, 2019–2025

Across 14 payments — averaging $1304.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$17K
  • GSK$941

What the payments were for

  • Consulting fees$38,78947%
  • Speaking & faculty fees$34,07542%
  • Travel & lodging$5,9907%
  • Food & beverage$2,8634%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.42$674,194
Eli Lilly42$325,177
GSK130$205,179
Astrazeneca UK Limited30$187,830
Takeda Pharmaceuticals U.S.A., Inc.88$92,318
Genentech, Inc.25$83,324
UCB SA17$81,132
Amgen(2 entities)6$46,565
AbbVie11$32,234
Pfizer26$31,025
AstraZeneca29$30,497
Aurinia Pharma U.S., Inc.25$23,135
Astrazeneca AB1$9,850
Novartis2$3,046
UCB, Inc.15$2,295
Biogen1$2,180
Janssen Research & Development, LLC1$82

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,830,063 in reported general payments places this provider in the 95th percentile of 67 rheumatology providers in Oklahoma.

See all rheumatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$150,230
Medicare patients
25
Services billed
6,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BenlystaBelimumab30$145,002
Cosentyx Sensoready PenSecukinumab12$89,615
Mycophenolate Mofetil50$5,256
Hydroxychloroquine Sulfate134$4,429
Leflunomide20$1,555
Azathioprine15$437
Prednisone80$418
MethotrexateMethotrexate Sodium43$343
Gabapentin25$152
Duloxetine Hcl18$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBenlysta$205,179$145,00230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 rheumatology providers in Oklahoma.

Other rheumatology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →